Literature DB >> 10650230

Safety and efficacy of diclofenac ophthalmic solution in the treatment of corneal abrasions.

P A Szucs1, A H Nashed, J R Allegra, B Eskin.   

Abstract

STUDY
OBJECTIVE: To determine whether the use of diclofenac ophthalmic solution is a safe and effective analgesic in the treatment of traumatic corneal abrasions in the emergency department.
METHODS: We conducted a prospective, randomized, double-blinded, placebo-controlled clinical trial. Consenting consecutive patients with corneal abrasions who presented to a community-based ED from August through February 1998 were randomly assigned to receive either diclofenac or control vehicle drops. Pain relief was measured using a visual Numeric Pain Intensity Scale (NPIS) before and after treatment. Exclusion criteria were as follows: age younger than 18 years, pregnancy, history of glaucoma, ocular infection, recent eye surgery, other signs of ocular trauma, narcotics within 6 hours, minimal pain (NPIS score <3), and any allergy to diclofenac or nonsteroidal anti-inflammatory drugs. Patients were discharged with study drug or control vehicle solution, a topical antibiotic, oxycodone-acetaminophen as a rescue analgesic, and a pain diary. The outcome measurements were improvement in NPIS score 2 hours after treatment, use of oxycodone-acetaminophen, and occurrence of any adverse effects.
RESULTS: Forty-nine patients were enrolled in the study; 25 received diclofenac and 24 received control vehicle drops. Both groups were similar in gender, age, pretreatment pain duration, NPIS score, and analgesic use. There was significantly greater improvement in the 2-hour NPIS score in the diclofenac group (3.1; 95% confidence interval [CI] 2.3 to 4) compared with the control group (1.0; 95% CI 0.1 to 2.0). The difference between the 2 groups was 2.1+/-1.3 (95% CI 0.8 to 3.4). There was a trend toward fewer patients taking rescue oxycodone-acetaminophen in the diclofenac group (20%; 95% CI 4% to 36%) versus the control group (42%; 95% CI 22% to 62%). Other than transient mild stinging, there were no complications associated with diclofenac use.
CONCLUSION: Diclofenac ophthalmic solution appears to be a safe and effective analgesic in the treatment of traumatic corneal abrasions in the ED.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10650230     DOI: 10.1016/s0196-0644(00)70132-6

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  8 in total

Review 1.  Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review.

Authors:  Bruce I Gaynes; Richard Fiscella
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Management of Ocular Trauma in Emergency (MOTE) Trial: A pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma.

Authors:  Joseph Y S Ting; Kenneth J Barns; John L Holmes
Journal:  J Emerg Trauma Shock       Date:  2009-01

3.  Corneal abrasion.

Authors:  Scott Fraser
Journal:  Clin Ophthalmol       Date:  2010-05-06

Review 4.  Burning Eye Syndrome: Do Neuropathic Pain Mechanisms Underlie Chronic Dry Eye?

Authors:  Jerry P Kalangara; Anat Galor; Roy C Levitt; Elizabeth R Felix; Ramon Alegret; Constantine D Sarantopoulos
Journal:  Pain Med       Date:  2015-12-24       Impact factor: 3.750

5.  Topical nonsteroidal anti-inflammatory drugs for corneal abrasions in children.

Authors:  Christine H Smith; Ran D Goldman
Journal:  Can Fam Physician       Date:  2012-07       Impact factor: 3.275

Review 6.  Efficacy of Topical Analgesics in Pain Control for Corneal Abrasions: A Systematic Review.

Authors:  Bryan Thiel; Alexandra Sarau; Daniel Ng
Journal:  Cureus       Date:  2017-03-27

7.  Management of traumatic corneal abrasion by a sample of practicing ophthalmologists in Saudi Arabia.

Authors:  Ghadah S Al-Saleh; Abdullah M Alfawaz
Journal:  Saudi J Ophthalmol       Date:  2017-10-31

Review 8.  Is the Sex Difference a Clue to the Pathomechanism of Dry Eye Disease? Watch out for the NGF-TrkA-Piezo2 Signaling Axis and the Piezo2 Channelopathy.

Authors:  Balázs Sonkodi; Miklós D Resch; Tibor Hortobágyi
Journal:  J Mol Neurosci       Date:  2022-05-04       Impact factor: 2.866

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.